Compare Intuit Inc. (INTU) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuit Inc. vs Twist Bioscience Corp — how do they compare? Intuit Inc. trades at $279.58 (market cap $80.37B), while Twist Bioscience Corp trades at $88.43 (market cap $5.45B). The key difference: Intuit Inc. is far larger — about 14.7× Twist Bioscience Corp's market cap, and Intuit Inc. pays a 1.63% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| INTU | TWST | |
|---|---|---|
Market Cap | $80.37B | $5.45B |
Sector | Technology | Health |
52-Week High | $807.39 | $102.88 |
52-Week Low | $255.07 | $24.16 |
Enterprise Value | $78.83B | $5.37B |
Dividend Yield | 1.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $293.82, up 0.94% on the day, with a bullish technical signal and strong fundamental performance. Recent earnings beats, including Q1 2026 EPS of $12.8 versus $12.57 expected, highlight robust profitability. The stock faces headwinds from legal investigations into pricing disclosures, contributing to a 20% drop from 2025 highs, but maintains a consensus analyst price target of $423.11 with 71% buy ratings.
The outlook is mixed: strong revenue growth and AI-driven product expansion support upside, but legal risks and competitive pressures pose significant threats. Investors should weigh the company's solid financials against ongoing litigation and market sentiment shifts for balanced risk-reward assessment.
Twist Bioscience (TWST) trades at $87.41, down 6.86% today, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst consensus is strongly bullish with 11 buy ratings and a $91.63 price target, while recent news highlights AI-driven drug discovery collaborations and upcoming Q3 earnings.
The stock presents growth potential through expanding synthetic biology applications and AI partnerships, but carries significant risk from persistent losses, negative cash flow, and high valuation multiples (P/S 13.94). Investors should weigh the company's innovation trajectory against its path to profitability amid competitive biotech pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
